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Abstract
Relapse in ANCA-associated vasculitis (AAV) has been studied previously, but there are
few studies on renal relapse in particular. Identifying patients at high risk of renal relapse
may aid in optimizing clinical management. We investigated which clinical and histological
parameters are risk factors for renal relapse in ANCA-associated glomerulonephritis
(AAGN). Patients (n = 174) were newly diagnosed and had mild–moderate or severe renal
involvement. Data were derived from two trials of the European Vasculitis Society: MEPEX
and CYCAZAREM. The Cox regression model was used to identify parameters increasing
the instantaneous risk (= rate) of renal relapse (useful for instant clinical decisions). For
identifying predictors of renal relapse during follow-up, we used Fine & Gray’s regression
model. Competing events were end-stage renal failure and death. The cumulative incidence
of renal relapse at 5 years was 9.5% (95% CI: 4.8–14.3%). In the Cox model, sclerotic class
AAGN increased the instantaneous risk of renal relapse. In Fine & Gray’s model, the
absence of interstitial infiltrates at diagnosis was predictive for renal relapse. In this study
we used two different models to identify possible relationships between clinical and histo-
pathological parameters at time of diagnosis of AAV with the risk of experiencing renal
relapse. Sclerotic class AAGN increased the instantaneous risk of renal relapse. This asso-
ciation is most likely due to the high proportion of sclerosed glomeruli reducing the compen-
satory capacity. The absence of interstitial infiltrates increased the risk of renal relapse
which is a warning sign that patients with a relatively benign onset of disease may also be
prone to renal relapse. Renal relapses occurring in patients with sclerotic class AAGN and
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renal relapses occurring in patients without interstitial infiltrates were mutually exclusive,
which may indicate that they are essentially different.
Introduction
Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are the major
subtypes of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Approximately 80% of patients with GPA and 90% with MPA develop kidney involvement
during the disease course.[1] ANCA-associated glomerulonephritis (AAGN) progresses to
end-stage renal failure (ESRF) in approximately 20–40% of patients.[2–5] The gold standard
for establishing AAGN is a renal biopsy, which typically shows a pauci-immune necrotizing
crescentic glomerulonephritis,[6,7] which can be grouped into four classes.[8] Relapse in
ANCA-associated vasculitis has been studied previously, but there are few studies on renal
relapse in particular. It is important to find a balance between the risk of relapse and the risk of
treatment-related adverse effects.
Identifying patients at high risk of renal relapse may aid in optimizing clinical management.
Previous relevant studies mainly focused on relapse in general with clinical data,[2,5,9–19]
identifying proteinase 3 (PR3)-ANCA, GPA, lung or cardiovascular involvement, and better
renal function at presentation as associated with relapse in general.[2,10–14,16,17,19] Note
that different statistical analyses were used in these reports to determine the influence of vari-
ous parameters on relapse; some published studies employed Fine & Gray’s regression model
while others used the standard Cox regression model. Both models are correct but address dif-
ferent research questions.
If more than one endpoint can occur, a competing risk analysis must be performed. In the
case of renal relapse, ESRF and death are competing events, because the occurrence of one of
them preclude the occurrence of renal relapse. Fine & Gray’s regression model is used to esti-
mate the effect of a risk factor on the cumulative incidence of renal relapse (CIR), which
denotes the probability of experiencing renal relapse before time t. The classical Cox regression
model is used to investigate the effect of risk factors on the rate of renal relapse. The parame-
ters in the Cox regression model are hazard ratios and the interpretation is the traditional one.
Note that relationships between risk factors (or explanatory parameters) and cause-specific
hazards do not lead to simple relationships between explanatory variables and cumulative inci-
dence. It is important to emphasize that both approaches are valid but that they answer differ-
ent research questions and may render different results. Thus the effect of a parameter on the
CIR might be different from its effect on the rate of renal relapse. Estimation based on Fine &
Gray’s model is useful for making predictions from the start of the disease, whereas the rate
looks at parameters that increase the instantaneous risk of renal relapse and is useful for instant
clinical decisions. In the present study, we apply both methods and discuss implications from
their results.
We investigated whether diagnostic clinical and histological parameters are associated with
renal relapse in patients with AAV with primary renal involvement. The study aim was to
identify diagnostic tools that may be helpful in monitoring and managing patients with AAV,
in particular in relation to renal relapse.
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Material and Methods
Patients
Patients included in this study were newly diagnosed with AAV with either mild to moderate
or severe renal involvement (serum creatinine or > 500 μmol/L ( or > 5.8 mg/dl)).
Patients were derived from two international multicenter randomized clinical European Vas-
culitis Society (EUVAS) trials: MEPEX and CYCAZAREM.[11,20] Inclusion criteria for both
trials are described elsewhere.[11,20] The diagnosis was based on a clinical presentation com-
patible with ANCA-associated vasculitis and substantiated by a positive ANCA serology and/
or histology.
The MEPEX and CYCAZAREM trial follow-up continued until 12 and 18 months after diag-
nosis, respectively. During the trials, patients received protocolized treatment regimens.[11,20]
After these follow-up periods, patients were treated according to their local physician’s stan-
dards. Patients were included and followed-up in the period June 1, 1995, through 30 Novem-
ber, 2006. Patients were included in this study only if histological data obtained from renal
biopsy at the time of study entry, clinical data, and long-term follow-up data were available.
Disease definitions were adapted from the Chapel Hill Consensus Conference on the
Nomenclature of Systemic Vasculitis and a previous European Union Study.[21,22] Both trials
were conducted according to the 1964 Declaration of Helsinki and subsequent amendments.
The trials were approved by the local ethics committees of the participating centers throughout
Europe. All patients gave written informed consent. The ethics for the use of the data and mate-
rial for subsequent studies, including this study, was approved by the West Midlands Multi-cen-
tre Research Ethics Committee, date 22/09/2004 (reference number: MREC/98/7/37). In
addition, this study was performed according to the ’Netherlands Code of Conduct for Scientific
Practice’, an ethical code for performing observational studies with patient material approved by
the Federatie van Medisch Wetenschappelijke Verenigingen (translated: Federation of Medical
Scientific Organisations) together with the legal and ethical committee of the Koninklijke
Nederlandse Akademie van Wetenschappen (translated: Royal Dutch Academy of Science) and
the Nederlandse Organisatie voor Wetenschappelijk Onderzoek (translated: Dutch Organisa-
tion for Scientific Research). The data of the patients were analyzed anonymously.
Clinical and histological parameters
Candidate parameters for clinical predictors of renal relapse in this study were serum creati-
nine levels, age, sex, diagnosis (GPA or MPA), ANCA-antigen specificity (PR3-ANCA or mye-
loperoxidase (MPO)-ANCA), and receiving plasma exchange during induction therapy.
Patients were subdivided into two groups of GPA and MPA based on the clinical criteria.
Renal-limited vasculitis was regarded as a form of MPA.
Candidate parameters for histological predictors were determined from paraffin sections of
renal biopsies. Stains used for evaluation were silver, periodic acid–Schiff, hematoxylin and
eosin, and trichrome. Sections were reviewed by two of a panel of five participating patholo-
gists (IMB, FF, LHN, RW, and/or JAB). Both pathologists, blinded to patient data and the
other observer’s results, scored the biopsies separately and according to a previously standard-
ized protocol, which was proven to be comprehensive and reproducible when used for histo-
logic analysis.[23] One of the histological parameters included in this previously standardized
protocol is interstitial infiltrates. Interstitial infiltrates were scored according to the following
categories:
• None:<10% of the unscarred parenchyma infiltrated.
• Mild: 10 to 25% of the unscarred parenchyma infiltrated.
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• Quite dense: 26 to 50% of the unscarred parenchyma infiltrated.
• Very dense: >50% of the unscarred parenchyma infiltrated.
In this study, only biopsies with a minimum of seven whole glomeruli were analyzed for
glomerular lesions and the histopathological classification system of AAGN.[8] During plenary
meetings, the panel of five pathologists decided upon the final scores to achieve consensus for
each biopsy.
Clinical outcomes
The clinical outcome parameter was first renal relapse. A renal relapse was defined as a rise in
serum creatinine of>30% or a fall in estimated glomerular filtration rate>25% and/or new
hematuria or proteinuria (all attributable to active vasculitis), as indicated by the Birmingham
Vasculitis Activity Score.[24–26] Patients were followed up until the last visit or death.
Statistical analyses
In this study, more than one endpoint could occur, namely renal relapse, ESRF, or death. The
event of interest was renal relapse, while ESRF and death were competing events. Two regres-
sion models used in the competing risks framework were estimated here: Fine & Gray’s model
and Cox model. To study the effect of risk factors on the CIR the former model is employed
while the latter is used to study the effects of risk factors on the rate of renal relapse, i.e. the
cause-specific hazard. For more details concerning the difference between the two models, see
Andersen et al. and Koller et al.[27,28] The technical aspects of competing risks were described
previously by Putter et al. [29]
Univariate analyses with both methods were performed on every clinical and histological
parameter. These analyses were performed on all patients without ESRF at baseline (n = 149),
except for glomerular lesions and the histopathological class of AAGN. In addition, we per-
formed a χ2-test to see whether the percent of renal relapse differed significantly between the
histopathological classes. Also a Pearson correlation test was performed to investigate whether
the presence of interstitial infiltrate was correlated with interstitial fibrosis. All baseline param-
eters were included as fixed covariates.
Because of the number of parameters (13 in this study) and the relatively low number of
events, inclusion of too many parameters carries the risk of “overfitting.”[30] Therefore, prede-
fined smaller sets of entry parameters were included in the multivariate analyses, as follows:
based on the original publication of the histopathological classification system of AAGN[8];
based on parameters described previously more than once as being associated with relapse;
and based on only histological parameters.
We denoted hazard ratios estimated by employing Cox regression model as cause-specific
hazard ratio (csHR) and the hazard ratios estimated by using Fine & Gray’s regression model
as Fine & Gray’s HR (F&G HR). All hazard ratios are provided with 95% confidence intervals
(CI). A P value of less than 0.05 was considered significant. Statistical analyses were performed
in SPSS (version 20.0; SPSS Inc, Chicago, IL) and R 2–18 (http://cran.r-project.org). All analy-
ses concerning competing risks were performed with the mstate library.[31,32]
Results
Patients
A total of 174 patients with newly diagnosed AAV and a renal biopsy at diagnosis were
included in this study. Table 1 shows the baseline patient characteristics. The median follow-
up time was 102 months (range: 38–136 months).
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Renal relapse
Of the 174 patients, 25 could not experience a renal relapse because they had ESRF at baseline.
Of the remaining 149 patients, 22 were chronic kidney disease (CKD) stage 1–2 and 127 were
CKD stage 3–5. Of these 22 CKD stage 1–2 patients, 5 (22.7%) developed CKD stage 3–5
within 5 years of follow-up. None of these 5 had experienced a renal relapse. In total, 31
patients experienced a renal relapse during follow-up. The CIR at 5 years was 9.5% (95% CI:
4.8–14.3%). A total of 19 patients developed ESRF during follow-up without experiencing
renal relapse, and 29 died without experiencing renal relapse and without developing ESRF
during follow-up. All patients who died during the follow-up period had CKD stage 3 at
baseline. Seventy patients had none of these events during follow-up (Figs 1 and 2).
Of the 149 patients, 113 had adequate renal tissue samples (at least seven whole glomeruli
in the renal biopsy) for classification purposes. Their diagnostic renal biopsies were classified
as follows: 23 focal class (20.4%), 58 crescentic class (51.3%), 18 mixed class (15.9%), and 14
sclerotic class (12.4%) (Table 2). Of these 113 patients, 24 experienced a renal relapse during
Table 1. Baseline characteristics of all patients.
Characteristic Value
Number of patients 174
Age (years) 60.3 ± 13.1a
Male 94 (54)
Diagnosis
GPA 74 (43)
MPA 100 (57)
ANCA antigen
PR3 81 (47)
MPO 80 (46)
Negative 7 (4)
Double positive 3 (2)
NR 3 (2)
Serum creatinine
 100 μmol/L 23 (13)
101–200 μmol/L 23 (13)
>201 μmol/L 128 (74)
ESRF at baseline 25 (14)
PLEX therapy
Yes 46 (26)
No 128 (74)
Histopathological classb
Focal 23 (20)
Crescentic 58 (51)
Mixed 18 (16)
Sclerotic 14 (12)
Data are presented as n (%) unless otherwise noted.
Abbreviations: ANCA, anti-neutrophil cytoplasmic antibody; ESRF, end-stage renal failure; GPA, granulomatosis with polyangiitis; MPA, microscopic
polyangiitis; MPO, myeloperoxidase; NR, not reported/not performed; PLEX, plasma exchange therapy; PR3, proteinase 3.
aMean (SD).
bOnly patients with at least 7 whole glomeruli in their renal biopsy and no ESRF at baseline.
doi:10.1371/journal.pone.0165402.t001
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follow-up. The numbers of patients having a renal relapse per class were 5/23 (21.7%) focal
class, 9/58 (15.5%) crescentic class, 4/18 (22.2%) mixed class, and 6/14 (42.9%) sclerotic class
(χ2-test: P = 0.167). The distribution of patient ages did not differ across classes. In particular,
patients from the sclerotic class were not older than those in other classes. During the trials,
therapies given to the patients did not differ among the four classes. Fourteen patients devel-
oped ESRF during follow-up without experiencing renal relapse (competing event 1). Twenty
patients died without experiencing renal relapse and without developing ESRF during follow-
up (competing event 2) (Fig 3).
Competing risks analyses
To investigate which parameters are associated with the CIR, Fine & Gray’s regression model
was used. The traditional Cox regression model was used to estimate the effect of the parame-
ters on the rate of renal relapse.[27]
Fine & Gray’s regression model
The univariate analyses showed that age, interstitial infiltrates, and intra-epithelial infiltrates
were associated with CIR (Table A in S1 File). Older age was associated with a lower risk for
experiencing a renal relapse. Higher scores of interstitial infiltrates and intra-epithelial infil-
trates, which are both signs of acute disease activity, were associated with a lower risk for renal
relapse. The histopathological class and CKD stage were not significantly associated with the
risk of renal relapse.
Among all histological parameters, only interstitial infiltrates had a significant association
on the risk of renal relapse (the CIR) in the multivariate analysis (Table 3). Although there was
a correlation between interstitial infiltrates and interstitial fibrosis, this correlation was rela-
tively weak (r = 0.236, P = 0.004). Therefore, interstitial fibrosis was not predictive for renal
relapse. Patients with mild infiltrates had a four times lower risk for renal relapse than patients
Fig 1. Events. Overview of different events experienced by 174 patients during follow-up. Twenty-five
patients presented with ESRF at baseline. Nineteen of them died during follow-up. Thirty-one patients
experienced renal relapse during follow-up; six of them developed ESRF, of whom four died, and three died
without ESRF during follow-up. Nineteen patients developed ESRF without renal relapse (competing event 1),
of whom 10 died at a later timepoint. Twenty-nine patients died without experiencing renal relapse or ESRF
(competing event 2). Seventy patients experienced no event during follow-up. Abbreviations: DSF, disease-
free survival; ESRF, end-stage renal failure; ESRF0, end-stage renal failure at baseline.
doi:10.1371/journal.pone.0165402.g001
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without interstitial infiltrates (F&G HR: 0.09; 95% CI: 0.02–0.39; P = 0.001). This association
persisted when correcting for the patient cohort indicator.
Among all clinical parameters, only age, corrected for other parameters, was associated
with patients experiencing a renal relapse (Table B in S1 File).
Cox regression model for renal relapse
Among all baseline parameters, only the histopathological class was a significant risk factor for
renal relapse in the univariate analyses (Table C in S1 File). CKD stage was not associated with
renal relapse. After correction for age, baseline serum creatinine, and plasma exchange ther-
apy, the histopathological class remained the only statistical significant risk factor for
experiencing a renal relapse (Table 4). Focal and crescentic class biopsies were associated with
a lower cause-specific hazard ratio compared to sclerotic class biopsies. Focal class had a 10.1
times lower rate than the sclerotic class (csHR: 0.10; 95% CI: 0.02–0.60; P = 0.01), and crescen-
tic class had a 4.7 times lower rate than the sclerotic class (csHR: 0.21; 95% CI: 0.07–0.62;
P = 0.004). Patient cohort (MEPEX or CYCAZAREM) did not affect these associations.
With the inclusion of histopathological class, baseline serum creatinine, ANCA type, and
diagnosis, only the histopathological class was a significant risk factor for renal relapse
(Table 5). Again, focal and crescentic classes were associated with a lower rate compared to
Fig 2. Cumulative incidence of renal relapse, end-stage renal failure or death. Cumulative incidence of
patients who experienced renal relapse (event of interest) and patients who developed ESRF or died
(competing events). This figure illustrates the probability of experiencing a renal relapse and the probability of
developing ESRF or dying without experiencing a renal relapse. Abbreviations: CI, cumulative incidence;
ESRF, end-stage renal failure.
doi:10.1371/journal.pone.0165402.g002
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Table 2. Baseline characteristics of patients per histopathological class.
Characteristic Value per class
Focal class Crescentic class Mixed class Sclerotic class
Number of patients 23 58 18 14
Age (years) 55.4 ± 13.8a 60.4 ± 13.6a 59.8 ± 9.2a 63.8 ± 12.3a
Male 14 (61) 28 (48) 11 (61) 6 (43)
Diagnosis
GPA 16 (70) 25 (43) 6 (33) 3 (21)
MPA 7 (30) 33 (57) 12 (67) 11 (79)
ANCA antigen
PR3 17 (74) 28 (48) 8 (44) 3 (21)
MPO 5 (22) 25 (43) 9 (50) 11 (79)
Negative 0 (0) 2 (4) 1 (6) 0 (0)
Double positive 1 (4) 2 (4) 0 (0) 0 (0)
NR 0 (0) 1 (2) 0 (0) 0 (0)
Serum creatinine
 100 μmol/L 14 (61) 1 (2) 1 (6) 0 (0)
101–200 μmol/L 3 (13) 7 (12) 3 (17) 3 (21)
>201 μmol/L 6 (26) 50 (86) 14 (78) 11 (79)
PLEX therapy
Yes 1 (4) 18 (69) 5 (28) 4 (29)
No 22 (96) 40 (31) 13 (72) 10 (71)
Data are presented as n (%) unless otherwise noted.
Sample size: 113 patients (patients with at least 7 whole glomeruli in their renal biopsy and no end-stage renal failure at baseline).
Abbreviations: ANCA, anti-neutrophil cytoplasmic antibody; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; MPO, myeloperoxidase;
NR, not reported/not performed; PLEX, plasma exchange therapy; PR3, proteinase 3.
aMean (SD).
doi:10.1371/journal.pone.0165402.t002
Fig 3. Events of the 113 patients with7 glomeruli in their renal biopsy without end-stage renal
failure at baseline. Twenty-four patients experienced a renal relapse during follow-up. Of these 24 patients,
four developed ESRF, of which three died, and four died without ESRF during follow-up. Fourteen patients
developed ESRF without renal relapse (competing event 1), of whom 7 died at a later timepoint. Twenty
patients died without renal relapse and without ESRF (competing event 2). Fifty-five patients experienced no
event during follow-up. Abbreviations: DSF, disease-free survival; ESRF, end-stage renal failure.
doi:10.1371/journal.pone.0165402.g003
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Table 3. Multivariate analysis with Fine & Gray’s model based on histological parameters.
Parameter Renal relapse
P Value F&G HR (95% CI)
Interstitial infiltrates
None - 1
Mild 0.001 0.09 (0.02–0.39)
Quite dense 0.1 0.16 (0.02–1.56)
Very dense 0.5 0.29 (0.01–7.83)
Interstitial fibrosis
None - 1
Focal 0.9 1.06 (0.24–4.67)
Diffuse 0.7 1.59 (0.19–13.44)
Tubular atrophy
None - 1
Small foci 0.7 1.44 (0.23–8.85)
Extensive 0.9 0.87 (0.05–14.34)
Intra-epithelial infiltratesa 0.2 0.34 (0.05–2.08)
Histopathological class
Focal 0.2 0.21 (0.02–2.11)
Crescentic 0.3 0.40 (0.08–2.00)
Mixed 0.9 1.06 (0.18–6.11)
Sclerotic - 1
Sample size: 112 patients
Abbreviations: 95% CI, 95% confidence interval; NS, not significant; F&G HR, Fine and Gray’s hazard ratio.
aReference group: No intra-epithelial infiltrates.
doi:10.1371/journal.pone.0165402.t003
Table 4. Multivariate analyses with both models based on the original publication of the histopathological classification system of ANCA-associ-
ated glomerulonephritis (Berden et al, 2010 [8]).
Parameter Renal relapse
Cox regression model Fine & Gray’s model
P Value csHR (95% CI) P Value F&G HR (95% CI)
Serum creatinine
 100 μmol/L - 1 - 1
101–200 μmol/L 0.6 0.65 (0.11–3.70) 0.6 0.58 (0.07–4.66)
>201 μmol/L 0.4 0.45 (0.08–2.43) 0.4 0.42 (0.05–3.80)
Age 0.3 0.98 (0.96–1.01) 0.02 0.97 (0.94–0.996)
Plasma exchange therapya 0.9 1.10 (0.33–3.69) 0.8 0.85 (0.23–3.14)
Histopathological class
Focal 0.01 0.10 (0.02–0.60) 0.2 0.24 (0.03–2.19)
Crescentic 0.004 0.21 (0.07–0.62) 0.07 0.34 (0.10–1.09)
Mixed 0.08 0.31 (0.08–1.15) 0.6 0.68 (0.18–2.58)
Sclerotic - 1 - 1
Sample size: 113 patients
Abbreviations: 95% CI, 95% confidence interval; csHR, cause-specific hazard ratio; NS, not significant; F&G HR, Fine and Gray’s hazard ratio.
aReference group: No plasma exchange therapy received.
doi:10.1371/journal.pone.0165402.t004
Renal Relapse in ANCA-Associated Glomerulonephritis
PLOS ONE | DOI:10.1371/journal.pone.0165402 December 14, 2016 9 / 15
sclerotic class. In this model, focal class had a 10.8 times lower rate than the sclerotic class
(csHR: 0.09; 95% CI: 0.02–0.55; P = 0.009), and crescentic class had a 4.8 times lower hazard
rate than the sclerotic class (csHR: 0.21; 95% CI: 0.07–0.64; P = 0.006). There was no effect of
patient cohort on these associations.
Discussion
This study shows that the histopathological class of AAGN in the renal biopsy at diagnosis is a
risk factor for renal relapse. More specifically, sclerotic class was associated with a higher rate
of renal relapse during long-term follow-up. It is important to emphasize that the effect of scle-
rotic class on the risk of renal relapse, i.e. the cumulative incidence, estimated by the Fine &
Gray’s model is different from its effects on the rate, i.e. the cause-specific hazard, estimated by
the Cox regression proportional hazard model. This is because the way in which risk factors
(or explanatory variables) are associated with the cause-specific hazards may not coincide with
the way these covariates are associated with the cumulative incidence. The sclerotic class in
AAGN is defined by50% globally sclerosed glomeruli, meaning that the majority of glomer-
uli are non-functioning and that the compensatory ability of the kidneys is relied on heavily.
Therefore, in these patients, a renal relapse may become more readily apparent because the
compensatory capacity of a sclerotic class kidney is reduced. Moreover, with fewer functioning
glomeruli, these glomeruli may become more vulnerable to a second hit, i.e., a relapse. In
patients with AAGN that is not in the sclerotic class, minor relapses may remain subclinical
because of the relatively higher number of preserved glomeruli and their compensatory ability.
Patients’ treatments were not based on the histopathological classification. Therefore, the scle-
rotic class may provide a setting in which renal relapse may be more likely to be detected than
in the setting of another histopathological class.
Table 5. Multivariate analyses with both models based on previously described parameters associated with relapse.
Parameter Renal relapse
Cox regression model Fine & Gray’s model
P Value csHR (95% CI) P Value F&G HR (95% CI)
Serum creatinine
 100 μmol/L - 1 - 1
101–200 μmol/L 0.6 0.62 (0.12–3.33) 0.5 0.44 (0.05–3.62)
>201 μmol/L 0.4 0.46 (0.08–2.65) 0.2 0.23 (0.02–2.61)
Diagnosisa 0.2 0.55 (0.20–1.51) 0.9 0.96 (0.24–3.87)
PR3-ANCAb 0.6 0.61 (0.09–4.22) 0.3 0.45 (0.10–2.03)
MPO-ANCAb 0.9 0.84 (0.14–5.07) 0.4 0.62 (0.21–1.79)
Histopathological class
Focal 0.009 0.09 (0.02–0.55) 0.3 0.32 (0.04–2.28)
Crescentic 0.006 0.21 (0.07–0.64) 0.2 0.46 (0.13–1.63)
Mixed 0.06 0.26 (0.07–1.07) 0.7 0.73 (0.18–2.98)
Sclerotic - 1 - 1
Sample size: 112 patients
Abbreviations: 95% CI, 95% confidence interval; ANCA, anti-neutrophil cytoplasmic antibody; csHR, cause-specific hazard ratio; MPO, myeloperoxidase;
NS, not significant; PR3, proteinase 3; F&G HR, Fine and Gray’s hazard ratio.
aReference group: Granulomatosis with polyangiitis.
bReference group: Negative.
doi:10.1371/journal.pone.0165402.t005
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To investigate the effect of risk factors on the risk of renal relapse, i.e. the cumulative inci-
dence, we applied Fine & Gray’s regression model. Results show that absence of interstitial
inflammatory infiltrates is associated with the risk of renal relapse. Patients with these infil-
trates had a lower risk for future renal relapse than patients without these inflammatory infil-
trates. The association of interstitial infiltrates with renal relapse persisted when corrected for
other histological parameters. Previous EUVAS studies focused on predictive clinical and sero-
logical parameters for relapse in general. Walsh et al. investigated clinical and serological
parameters predictive for relapse in general in a European cohort consisting of 535 patients. In
that study, PR3-ANCA, lower serum creatinine levels at presentation, cardiovascular involve-
ment, and GPA were independently associated with an increased risk for relapse, whether in
the kidney or any other organ.[19] Our study is based on the histopathological data of those
patients from the previous study by Walsh et al. who had a renal biopsy with sufficient tissue
for proper evaluation; thus, we could investigate which histological parameters are predictive
for renal relapse. Our finding that the absence of interstitial infiltrates is predictive for renal
relapse is in line with the finding by Walsh et al. that better renal function increases the risk for
a relapse in general because absence of interstitial infiltrates also correlates with better renal
function at the time of biopsy.[33,34] Experiencing a renal relapse has a negative influence on
renal outcome.[35] Therefore, clinicians should realize that renal relapses must be identified
and treated and keep in mind that those patients with a relatively benign clinical course at
onset in particular will be prone to developing a renal relapse.
This study shows a higher cumulative risk for ESRF or death compared to renal relapse as
shown in Fig 2. These results may have been influenced by the inclusion of patient from the
MEPEX trial which included patients with serum creatinine >500 μmol/L or immediate dialy-
sis dependency. Nineteen patients (11%) had ESRF during follow-up without experiencing a
(clinical) renal relapse. It is possible that these patients had subclinical renal relapses, but they
were not detected clinically. Based on this knowledge, we emphasize the need for chronic kid-
ney disease management and renal protective strategies.
Our study has a number of limitations. Because of the sample size and relatively low num-
ber of events, we were limited in the size of the predefined multivariate analyses. To avoid bias,
all multivariate analyses were predefined before the start of this study. To use the best possible
predefined analyses, we constructed them based on the literature regarding the histopatholog-
ical classification system of AAGN. Unfortunately, repeat biopsies during the time of renal
relapse were not performed because it is generally considered that the risk of taking a biopsy
would not weight against the benefit of a histologically proven renal relapse, keeping in mind
that these can be diagnosed with a high level of certainty on the basis of the clinical findings.
In conclusion, we used two regression models to identify possible relationships between
clinical and histopathological parameters at time of diagnosis of AAV with the risk of renal
relapse, i.e. the cumulative incidence, and the effect on the rate of renal relapse, i.e. the cause-
specific hazard. The effect of sclerotic class on the risk of renal relapse estimated by the Fine &
Gray’s regression model was different from its effects on the rate estimated by the Cox regres-
sion model. Most likely, the lack of compensatory function in the largely sclerosed kidneys
gives rise to the identification of a relatively high number of renal relapses. A strong predictive
parameter for renal relapse was the absence of interstitial infiltrates as determined with the
Fine & Gray model. Combining these results with those of previous studies, it seems that the
patient with AAV characterized by a relatively benign clinical setting at onset is prone to a
renal relapse. In this study, renal relapses occurring in patients with sclerotic class AAGN and
renal relapses occurring in patients without interstitial infiltrates were mutually exclusive,
which may indicate that they are essentially other kinds of relapses. Further studies are called
to look further into the characteristics of renal relapses in AAV, in particular to find out
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whether the histopathological data at disease onset could serve as a guideline for the manage-
ment of renal relapses in AAV.
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S1 File. Table A. Univariate analyses with Fine & Gray’s model.
Abbreviations: 95% CI, 95% confidence interval; ANCA, anti-neutrophil cytoplasmic anti-
body; CKD, chronic kidney disease; GPA, granulomatosis with polyangiitis; MPA, micro-
scopic polyangiitis; MPO, myeloperoxidase; NS, not significant PR3, proteinase 3; F&G dHR,
Fine and Gray’s hazard ratio.
aReference group: Female.
bReference group: Granulomatosis with polyangiitis.
cReference group: Negative.
dReference group: No plasma exchange therapy received.
eReference group: No intra-epithelial infiltrates.
Table B. Multivariate analysis with Fine & Gray’s model based on clinical parameters and
histopathological class.
Sample size: 112 patients
Abbreviations: 95% CI, 95% confidence interval; ANCA, anti-neutrophil cytoplasmic anti-
body; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; MPO, myelo-
peroxidase; NS, not significant; PR3, proteinase 3; F&G HR, Fine and Gray’s hazard ratio.
aReference group: Female.
bReference group: Granulomatosis with polyangiitis.
cReference group: Negative.
dReference group: No plasma exchange therapy received.
Table C. Univariate analyses with Cox regression model.
Abbreviations: 95% CI, 95% confidence interval; ANCA, anti-neutrophil cytoplasmic anti-
body; CKD, chronic kidney disease; csHR, cause-specific hazard ratio; GPA, granulomatosis
with polyangiitis; MPA, microscopic polyangiitis; MPO, myeloperoxidase; PR3, proteinase 3.
aReference group: Female.
bReference group: Granulomatosis with polyangiitis.
cReference group: Negative.dReference group: No plasma exchange therapy received.eRefer-
ence group: No intra-epithelial infiltrates.
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